Across TCGA pan-cancer cohorts, ZNF836 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF836 data layer compared with 28 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher ZNF836 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF836 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

KICH, UCEC, and BLCA are the cancer types where ZNF836 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.043	0.971	<.001	29	view →
UCEC	DFS	Median	All	0.944	0.614	.007	22	view →
BLCA	DFS	Median	II,III,IV	0.878	0.321	.021	13	view →
HNSC	DFS	Median	All	0.214	0.663	.012	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ZNF836 tumor-vs-normal RNA expression · all ZNF836 data types